Keros Therapeutics (KROS) Announces Proposed $120M Share Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Keros Therapeutics Announces Proposed Public Offering of Common Stock
January 3, 2024 4:05 PM ESTLEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (Keros) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins, today announced the launch of a proposed underwritten public offering of $120.0 million of shares of its common stock (the Offer Shares). All shares of common stock to be sold in the proposed offering will be sold by Keros. In addition, Keros expects to grant the underwriters a 30-day... More
